Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
Daiichi Sankyo
McKinsey
Teva
Medtronic
AstraZeneca
McKesson
Fish and Richardson

Generated: December 17, 2018

DrugPatentWatch Database Preview

Regulatory Exclusivity Expiring in 2020

« Back to Dashboard

Drugs with Regulatory Exclusivity Expiring in 2020

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Exclusivity Expiration Patented / Exclusive Use
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-002 Apr 30, 2013 RX Yes Yes ➤ Try a Free Trial UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-001 Apr 30, 2013 RX Yes No ➤ Try a Free Trial UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-001 Oct 29, 2007 RX Yes Yes ➤ Try a Free Trial TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes ➤ Try a Free Trial NEW PRODUCT
Novartis TASIGNA nilotinib hydrochloride CAPSULE;ORAL 022068-002 Jun 17, 2010 RX Yes No ➤ Try a Free Trial TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Try a Free Trial NEW CHEMICAL ENTITY
Actelion Pharms Ltd UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes Yes ➤ Try a Free Trial NEW CHEMICAL ENTITY
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Exclusivity Expiration Patented / Exclusive Use

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Covington
Harvard Business School
UBS
Express Scripts
Baxter
Federal Trade Commission
US Army
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.